from 31 Mar 2022 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
Summary: ELITE PHARMACEUTICALS INC /NV/ quarterly Deferred Income Tax Assets, Net in USD history and change rate from 31 Mar 2022 to 31 Dec 2025.
ELITE PHARMACEUTICALS INC /NV/ Deferred Income Tax Assets, Net for the quarter ending 31 Dec 2025 was $10,325,353, a 50% decline year-over-year.
Source SEC data: View on sec.gov

Deferred Income Tax Assets, Net, Quarterly (USD)

Deferred Income Tax Assets, Net, YoY Quarterly Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Deferred Income Tax Assets, Net (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2025	$10,325,353	-$10,364,028	-50%	31 Dec 2025	10-Q	17 Feb 2026	2026	Q3
Q3 2025	$11,804,166	-$9,039,338	-43%	30 Sep 2025	10-Q	14 Nov 2025	2026	Q2
Q2 2025	$13,481,213	-$8,661,473	-39%	30 Jun 2025	10-Q	14 Aug 2025	2026	Q1
Q1 2025	$18,365,748	-$3,795,147	-17%	31 Mar 2025	10-Q	17 Feb 2026	2026	Q3
Q4 2024	$20,689,381	+$455,778	+2.3%	31 Dec 2024	10-Q	13 Feb 2025	2025	Q3
Q3 2024	$20,843,504	+$1,410,336	+7.3%	30 Sep 2024	10-Q	14 Nov 2024	2025	Q2
Q2 2024	$22,142,686	+$19,970,865	+920%	30 Jun 2024	10-Q	14 Aug 2024	2025	Q1
Q1 2024	$22,160,895	+$19,989,074	+920%	31 Mar 2024	10-K	30 Jun 2025	2025	FY
Q4 2023	$20,233,603	+$18,061,782	+832%	31 Dec 2023	10-Q	14 Feb 2024	2024	Q3
Q3 2023	$19,433,168	+$17,261,347	+795%	30 Sep 2023	10-Q	14 Nov 2023	2024	Q2
Q2 2023	$2,171,821	$0	0%	30 Jun 2023	10-Q	14 Aug 2023	2024	Q1
Q1 2023	$2,171,821	$0	0%	31 Mar 2023	10-K	01 Jul 2024	2024	FY
Q4 2022	$2,171,821			31 Dec 2022	10-Q	14 Feb 2023	2023	Q3
Q3 2022	$2,171,821			30 Sep 2022	10-Q	14 Nov 2022	2023	Q2
Q2 2022	$2,171,821			30 Jun 2022	10-Q	15 Aug 2022	2023	Q1
Q1 2022	$2,171,821			31 Mar 2022	10-K	29 Jun 2023	2023	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.